KEI comments on the prospective grant of an exclusive patent license: Mutant IDH1 inhibitors useful for treating cancer to Apexx Oncology

July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer to Apexx… Continue Reading

NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancer

On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading

Litigation: KEI v. NIH et al.

On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. This page provides current information on this ongoing litigation. KEI blogs 2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR… Continue Reading

WHO publishes Meeting Report of the Informal Advisory Group on the Availability and Affordability of Cancer Medicines

In May 2017, the 70th World Health Assembly passed a cancer resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach). At the time KEI provided the following commentary on the cancer resolution: On Tuesday, May 30,… Continue Reading

WHA71: KEI intervention on Addressing the global shortage of, and access to, medicines and vaccines

21 May 2018 Knowledge Ecology International (KEI) intends to deliver the following statement on Addressing the global shortage of, and access to, medicines and vaccines. 11.5 Addressing the global shortage of, and access to, medicines and vaccines Documents A71/12 and… Continue Reading

Statement of Portugal: UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030

On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030… Continue Reading

KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite

KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading

Wikileaks

Posted August 27, 2011 These are some tools for searching the US Department of State cables released by Wikileaks. A Wikileaks page on the cables is available here: http://wlcentral.org/cablegate KEI recommends this site for searching the cables by key words:… Continue Reading

NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead

On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading